3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Conditions
Thrombocythemia, Essential
2
Myeloproliferative Disorders
2
Polycythemia Vera
1
Interventions
ruxolitinib
6
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Cytarabine
5
fludarabine phosphate
4
Whole-Body Irradiation
4
Methotrexate
4
Daunorubicin
4
Thioguanine
3
Tacrolimus
3
Etoposide
3
Early Intervention, Educational
3
Cyclophosphamide
3
ponatinib
2
parsaclisib
2
nilotinib
2
merphos
2
luspatercept
2
fludarabine
2
fedratinib
2
anagrelide
2
Tretinoin
2
Therapeutics
2
Psychiatric Rehabilitation
2
Mitoxantrone
2
Filgrastim
2
Cyclosporins
2
Cyclosporine
2
Busulfan
2
Asparaginase
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Myeloproliferative Disorders
×
anagrelide
×
Clear all
NCT04285086
2025-08-13
SURPASS ET
PharmaEssentia
Phase 3
Active not recruiting
174 enrolled
NCT02076815
2015-07-29
TEAM-ET
AOP Orphan Pharmaceuticals AG
Phase 3
Completed
106 enrolled